The core structures of roseophilin and the prodigiosin alkaloids define a new class of protein tyrosine phosphatase inhibitors

ChemBioChem

Volumn 5, Issue 11, 2004, Pages 1575-1579

  Fürstner, Alois ^a   Reinecke, Kerstin ^b   Prinz, Heino ^b   Waldmann, Herbert ^b,c  

^a MAX PLANCK INSTITUT FÜR KOHLENFORSCHUNG   (Germany)

^b MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^c TU DORTMUND UNIVERSITY   (Germany)

Author keywords

Alkaloids; Biological activity; Enzymes; Inhibitors; Phosphatases; Prodigiosin

Indexed keywords

ALKALOID; AZAFULVENE DERIVATIVE; DRUG METABOLITE; HETEROCYCLIC COMPOUND; NATURAL PRODUCT; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE VHR; PRODIGIOSIN; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE PTP1B; ROSEOPHILIN; UNCLASSIFIED DRUG;

ARTICLE; ENZYME INHIBITION; ENZYME KINETICS; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROCESS DESIGN; STREPTOMYCES; STREPTOMYCES GRISEOVIRIDIS; STRUCTURE ANALYSIS;

ALKALOIDS; ENZYME INHIBITORS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MOLECULAR STRUCTURE; PRODIGIOSIN; PROTEIN-TYROSINE-PHOSPHATASE; PYRROLES;

STREPTOMYCES; STREPTOMYCES GRISEOVIRIDIS;

EID: 8844259726     PISSN: 14394227     EISSN: None     Source Type: Journal    
DOI: 10.1002/cbic.200400135     Document Type: Article

References (42)

1. T. Hunter, Cell 2000, 100, 113-127.
2. a) K. Hinterding, D. Alonso-Díaz, H. Waldmann, Angew. Chem. 1998, 110, 716-780; Angew. Chem. Int. Ed. 1998, 37, 688-749;
3. a) K. Hinterding, D. Alonso-Díaz, H. Waldmann, Angew. Chem. 1998, 110, 716-780; Angew. Chem. Int. Ed. 1998, 37, 688-749;
4. b) J. E. Sheppeck, C.-M. Gauss, A. R. Chamberlin, Bioorg. Med. Chem. 1997, 5, 1739-1750.
5. A. McCluskey, A. T. R. Sim, J. A. Sakoff, J. Med. Chem. 2002, 45, 1151-1175.
6. a) R. H. van Huijsduijnen, A. Bombrun, D. Swinnen, Drug Discovery Today 2002, 7, 1013-1019;
7. b) Z.-Y. Zhang, Curr. Opin. Chem. Biol. 2001, 5, 416-423;
8. c) T. O. Johnson, J. Ermolieff, M. R. Jirousek, Nat. Rev. Drug Discovery 2002, 1, 696-709.
9. M. A. Lyon, A. P. Ducruet, P. Wipf, J. S. Lazo, Nat. Rev. Drug Discovery 2002, 1, 961-976.
10. a) Y. Hayakawa, K. Kawakami, H. Seto, K. Furihata, Tetrahedron Lett. 1992, 33, 2701-2704;
11. b) Information concerning the cytotoxicity of 1-HCl (NCl number 650718) against various human cancer cell lines in vitro is available from the NCl database on the Internet at http://www.dtp.nci.nih.gov.
12. N. N. Gerber, Crit Rev. Microbiol. 1974, 3, 469-485, and references therein.
13. A. Fürstner, Angew. Chem. 2003, 115, 3706-3728; Angew. Chem. Int. Ed, 2003, 42, 3582-3603.
14. A. Fürstner, Angew. Chem. 2003, 115, 3706-3728; Angew. Chem. Int. Ed, 2003, 42, 3582-3603.
15. a) R. A. Mandervllle, Curr. Med. Chem.: Anti-Cancer Agents 2001, 1, 195-218;
16. b) R. Pérez-Tomás, B. Montaner, E. Llagostera, V. Soto-Cerrato, Biochem. Pharmacol. 2003, 66, 1447-1452.
17. R. D'Alessio, A. Bargiotti, O. Carlini, F. Calotta, M. Ferrari, P. Gnocchi, A. Isetta, N. Mongelli, P. Motta, A. Rossi, M. Rossi, M. Tibolla, E. Vanotti, J. Med. Chem. 2000, 43, 2557-2565.
18. A. Fürstner, J. Grabowski, C. W. Lehmann, J. Org. Chem. 1999, 64, 8275-8280, and references therein.
19. A. Fürstner, J. Grabowski, C. W. Lehmann, T. Kataoka, K. Nagai, ChemBioChem 2001, 2, 60-68, and references therein.
20. A. Fürstner, E. J. Grabowski, ChemBioChem 2001, 2, 706-709, and references therein.
21. a) A. Fürstner, H. Szillat, B. Gabor, R. Mynott, J. Am. Chem. Soc. 1998, 120, 8305-8314;
22. b) A. Fürstner, H. Krause J. Org. Chem. 1999, 64, 8281-8286.
23. a) A. Fürstner, H. Weintritt, J. Am. Chem. Soc. 1998, 120, 2817-2825;
24. b) A. Fürstner, H. Weintritt, J. Am. Chem. Soc. 1997, 119, 2944-2945;
25. c) A. Fürstner, T. Gastner, H. Weintritt, J. Org. Chem. 1999, 64, 2361-2366.
26. D. Brohm, N. Philippe, S. Metzger, A. Bhargava, O. Müller, F. Lieb, H. Waldmann, J. Am. Chem. Soc. 2002, 124, 13171-13178.
27. a) L. Bialy, H. Waldmann, Angew. Chem. 2002, 114, 1819-1822; Angew. Chem. Int. Ed. 2002, 47, 1748-1751;
28. a) L. Bialy, H. Waldmann, Angew. Chem. 2002, 114, 1819-1822; Angew. Chem. Int. Ed. 2002, 47, 1748-1751;
29. b) L. Bialy, H. Waldmann, Chem. Commun. 2003, 1872-1873;
30. c) L. Bialy, H. Waldmann, Chem. Eur. J. 2004, 10, 2759-2780.
31. a) A. Fürstner, F. Feyen, H. Prinz, H. Waldmann, Angew. Chem. 2003, 115, 5519-5522; Angew. Chem. Int. Ed. 2003, 42, 5361-5364;
32. a) A. Fürstner, F. Feyen, H. Prinz, H. Waldmann, Angew. Chem. 2003, 115, 5519-5522; Angew. Chem. Int. Ed. 2003, 42, 5361-5364;
33. b) A. Fürstner, J. Ruiz-Caro, H. Prinz, H. Waldmann, J. Org. Chem. 2004, 69, 459-467.
34. a) J. L. Todd, K. G. Tanner, J. M. Denu, J. Biol. Chem. 1999, 274, 13271-13280;
35. b) T. Usui, S. Kojima, S. Kidokoro, K. Ueda, U. Osada, M. Sodeoka, Chem. Biol. 2001, 8, 1209-1220.
36. Reviews: a) K. Galaktionov, A. K. Lee, J. Eckstein, G. Draetta, J. Meckler, M. Loda, D. Beach, Science 1995, 269, 1575-1577;
37. b) G. Draetta, J. Eckstein, Biochim. Biophys. Acta 1997, 1332, M53-M63;
38. c) I. Nilsson, I. Hoffmann, Prog. Cell Cycle Res. 2000, 4, 107-114;
39. d) See also ref. [4b].
40. D. L. Boger, J. Hong, J. Am. Chem. Soc. 2001, 123, 8515-8519.
41. K. A. Alvi, A. Casey, B. G. Nair, J. Antibiot. 1998, 51, 515-517.
42. K. Galaktionov, D. Beach, Cell 1991, 67, 1181-1194.